G - Physics
01
N
G01N 33/50 (2006.01) G01N 33/569 (2006.01)
Patent
CA 2694278
The present invention concerns a method for identifying compounds that decrease the ability of Human Immunodeficiency Virus (HIV) to enter previously uninfected cells. More specifically it relates to a homogeneous competitive cell-based binding assay for the identification of HIV-1 entry fusion inhibitors on a high content screening platform or flow cytometric-based read out.
La présente invention concerne un procédé d'identification de composés capables de diminuer la capacité du virus de l'immunodéficience humaine (VIH) à pénétrer dans des cellules préalablement non infectées. Plus spécifiquement, la présente invention concerne un test compétitif homogène de liaison à base de cellules, qui permet l'identification d'inhibiteurs de fusion d'entrée HIV-1 sur une plate-forme d'essai à haute teneur ou un afficheur basé sur la cytométrie de flux.
Bunkens Lieve Elisabeth Louis
Dams Gery Karel Julia
Holemans Pascale Alice Jan
Meersseman Geert Henri
Ohagen Asa Catrine
Gowling Lafleur Henderson Llp
Tibotec Pharmaceuticals Ltd.
LandOfFree
Native gp41 assay does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Native gp41 assay, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Native gp41 assay will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1640510